November 29, 2022
A key health ministry advisory panel on November 28 recommended approval for a batch of medicines including Sanofi’s cemiplimab, which could become the third PD-1 inhibitor in Japan if approved. Cemiplimab, known as Libtayo overseas, is among the four new...read more